Infliximab maintenance therapy for fistulizing Crohn's disease
about
Epidemiology and clinical course of Crohn's disease: results from observational studiesEuropean evidence based consensus on the diagnosis and management of Crohn's disease: special situationsMaintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's DiseaseThalidomide and thalidomide analogues for maintenance of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseTumor necrosis factor-alpha antibody for maintenance of remission in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's diseasePostoperative enterocutaneous fistula: when to reoperate and how to succeedThe two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel diseaseInflammatory bowel disease surgery in the biologic eraAdvances in the development of new biologics in inflammatory bowel diseaseSelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabUstekinumab for the treatment of Crohn's disease: can it find its niche?Economic implications of biological therapy for Crohn's diseaseIntestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Current stage in inflammatory bowel disease: What is next?Medical Therapy of Perianal Crohn's DiseasePharmacologic therapy for inflammatory bowel disease refractory to steroidsHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseEvidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsInflammatory pathways of importance for management of inflammatory bowel diseaseInfliximab-Related Infusion Reactions: Systematic ReviewVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Use of the tumor necrosis factor-blockers for Crohn's diseaseUstekinumab in Crohn's disease: evidence to date and place in therapyTransperineal ultrasonography in perianal Crohn disease: A valuable imaging modalityReview article: Infliximab therapy for inflammatory bowel disease--seven years onPerianal Crohn's disease.Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Management of complex perianal Crohn's diseaseA multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyMedical management of Crohn's disease: current therapy and recent advances.Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Inflammatory Bowel Disease in Children and Adolescents
P2860
Q22241217-10EDD9CE-9155-4095-84C2-21BECC6D5851Q22242050-AC0205FA-E370-43BA-B346-01269449D137Q22242347-4FB46344-F038-4C9B-B360-89998AF8C2C3Q24241489-49DFD6BA-B0C0-41B5-B50E-114AF268908CQ24241766-C6223CD2-4F2D-46FF-8045-A67B8C928D10Q24242101-EF57809F-4BB5-44C2-8650-8D00AF390AE2Q24245127-18B899F9-4F19-4297-A735-94E9E5E72F65Q24653675-54DC4E8B-743A-44DF-93FF-2F1D7BEA223FQ26740549-E69141A4-1274-47CE-A0D6-0621098E3F5FQ26745627-7D57E153-F35C-4225-9387-67FD5FB18D0EQ26745782-CE4743B2-4270-4509-B3B6-98BBA2F2964EQ26750456-7AA2B467-DAAD-4DB1-A41C-1499877A2659Q26771890-99A4E321-154C-4F22-A98A-E7AEA796E7F1Q26772179-B4068C70-8677-496E-BCE2-D118905B7924Q26775240-669C6D3C-9F6C-44DE-BD17-41F09127508FQ26777409-F3E811CC-BB08-43D0-BFF0-CB883C85DB3CQ26777429-288CD3AD-CAA1-4C6C-ADCA-0647175ECD65Q26777722-98A03E53-7180-412E-9335-CD3E9718BBEBQ26796415-211B662B-D81A-4BF7-9435-37ACFA709ECEQ26827444-4B583080-7512-4330-BA43-56548F5EBD47Q26829392-46155108-C2BD-4D84-B0A7-DEF59A0B7FCCQ26829488-1572F259-D5B1-4E3E-A611-E2E2C374BFAEQ26991673-DECEFDA0-684E-48CF-A265-A535F66D5BA1Q26994776-E75C10C4-A08E-40BD-A6B7-1E13B87A67E3Q26999078-8B1ECDB6-41C4-4F45-9032-C01023548DEDQ27005445-8E014C6D-BC8C-43B2-B2DC-7A53DC980561Q27013835-DB1BD589-690D-4196-A273-2DE62B70B4C7Q27021612-1FFA3B73-702F-43FC-94ED-8EB1FC15B8EFQ27030762-BDF3B7BF-0487-4D7D-9A92-BB951489E181Q28073787-D5469769-FE6D-48D7-B875-C71A5C680ECCQ28088575-353AD2B6-2006-4AE2-BE43-BBE9E5AF3CF3Q28294134-F958B014-5A9B-4BB4-A60F-A51671EF6023Q29346975-5B71AF19-58DC-4097-889E-5492ECEEFDA9Q30234628-D350DE9B-CE2E-4940-8608-85AD4187A17EQ30239850-E9D801A9-A4B4-4440-BB3E-7A33443E08CAQ30430605-D8C1B990-FC7C-4BBA-B31B-1B2AB55D99CCQ30450875-D7B98C36-55B8-4CB4-AE1C-78A0E5789E6FQ30526431-E5AC410F-64F0-4A19-BBEB-65CF32825AE6Q30675199-DA2385C8-973B-4F5F-B24B-F1808B43E5C7Q30695348-699CF9A7-061D-40A1-91FA-665E56369FB1
P2860
Infliximab maintenance therapy for fistulizing Crohn's disease
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Infliximab maintenance therapy for fistulizing Crohn's disease
@ast
Infliximab maintenance therapy for fistulizing Crohn's disease
@en
Infliximab maintenance therapy for fistulizing Crohn's disease
@nl
type
label
Infliximab maintenance therapy for fistulizing Crohn's disease
@ast
Infliximab maintenance therapy for fistulizing Crohn's disease
@en
Infliximab maintenance therapy for fistulizing Crohn's disease
@nl
prefLabel
Infliximab maintenance therapy for fistulizing Crohn's disease
@ast
Infliximab maintenance therapy for fistulizing Crohn's disease
@en
Infliximab maintenance therapy for fistulizing Crohn's disease
@nl
P2093
P3181
P356
P1476
Infliximab maintenance therapy for fistulizing Crohn's disease
@en
P2093
Bret A Lashner
Bruce E Sands
Charles N Bernstein
Daniel Rachmilewitz
Douglas C Wolf
Frank H Anderson
Jane E Onken
Joshua R Korzenik
Marion A Blank
P304
P3181
P356
10.1056/NEJMOA030815
P407
P577
2004-02-26T00:00:00Z